Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC

被引：0
|
作者：
Nassar, Amin
Mouw, Kent William
Liu, Chia-Jen
Lundgren, Kevin
Van Allen, Eliezer Mendel
Harshman, Lauren Christine
Pomerantz, Mark
Preston, Mark A.
Wei, Xiao X.
McGregor, Bradley Alexander
Choudhury, Atish Dipankar
Bellmunt, Joaquim
Choueiri, Toni K.
Kwiatkowski, David J.
Sonpavde, Guru
机构：
[1] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Brookline, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[5] David Grant Med Ctr, Benicia, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4539
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Basis of PD1/PD-L1 Therapies
    Seliger, Barbara
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (12)
  • [12] Association of PD-L1 expression with survival benefit from PD-1/PD-L1 inhibitors in advanced cancer: Systematic review and meta-analysis of phase III randomized clinical trials
    Kuang, Xiaohong
    Xu, Run
    Li, Jian
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 198
  • [13] Host immunogenetics and hyperprogression under PD1/PD-L1 checkpoint inhibitors
    Refae, Sadal
    Ebran, Nathalie
    Gal, Jocelyn
    Otto, Josiane
    Giacchero, Damien
    Borchiellini, Delphine
    Guigay, Joel
    Peyrade, Frederique
    Milano, Gerard
    Saada, Esma
    CANCER RESEARCH, 2018, 78 (13)
  • [14] Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
    Merelli, Barbara
    Massi, Daniela
    Cattaneo, Laura
    Mandala, Mario
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 89 (01) : 140 - 165
  • [15] PD1 and PD-L1 expression in thymic lesions
    Bagir, E. Kilic
    Acikalin, A.
    Avci, A.
    Gumurdulu, D.
    Paydas, S.
    VIRCHOWS ARCHIV, 2017, 471 : S264 - S264
  • [16] ANALYSIS OF PD1 AND PD-L1 EXPRESSION IN GLIOBLASTOMA
    Berghoff, A. S.
    Kiesel, B.
    Widhalm, G.
    Woehrer, A.
    Dieckmann, K.
    Filipits, M.
    Marosi, C.
    Hainfellner, J. A.
    Preusser, M.
    Wick, W.
    NEURO-ONCOLOGY, 2014, 16
  • [17] Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma
    Chen, Qin
    Wang, Jing
    Wang, Xinyue
    Yin, Yan
    Wang, Xuan
    Song, Zhenchun
    Xing, Bin
    Li, Yajing
    Zhang, Jingjing
    Qin, Jianwen
    Jiang, Richeng
    CLINICAL LUNG CANCER, 2024, 25 (01) : 29 - 38
  • [18] Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumors
    Wang, Miao
    Zhen, Hongchao
    Jiang, Xiaoyue
    Lu, Yuting
    Wei, Yuhan
    Jin, Jiangtao
    Li, Qin
    IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1584 - 1595
  • [19] Germinal immunogenetics predicts treatment outcome for PD1 PD-L1 checkpoint inhibitors
    Refae, Sadal
    Gal, Jocelyn
    Ebran, Nathalie
    Otto, Josiane
    Borchiellini, Delphine
    Peyrade, Frederic
    Chamorey, Emmanuel
    Brest, Patrick
    Milano, Gerard Alain
    Saada-Bouzid, Esma
    CANCER RESEARCH, 2019, 79 (13)
  • [20] From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma
    Hussain, Syed A.
    Birtle, Alison
    Crabb, Simon
    Huddart, Robert
    Small, Diane
    Summerhayes, Maxwell
    Jones, Robert
    Protheroe, Andrew
    EUROPEAN UROLOGY ONCOLOGY, 2018, 1 (06): : 486 - 500
12345